-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on EyePoint Pharmaceuticals, Raises Price Target to $39

Benzinga·11/06/2025 15:54:17
Listen to the news
RBC Capital analyst Lisa Walter maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and raises the price target from $28 to $39.